Drug profile · INN
eculizumab
SOLIRIS
eculizumab (SOLIRIS) is a complement c5 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: iv (infusion). Current US regulatory status: approved.
Drug details — eculizumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- IV (INFUSION)
- Patents
- 0
- Programs
- 11
- Data quality
- 0.84
Quick answer
eculizumab (SOLIRIS) is a complement c5 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: iv (infusion). Current US regulatory status: approved.
Key facts
Mechanism of action
Complement C5 inhibitor
Primary target: Complement C5
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is eculizumab?
eculizumab (SOLIRIS) is a complement c5 inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: iv (infusion). Current US regulatory status: approved.
What is the brand name for eculizumab?
SOLIRIS is a marketed brand name for eculizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of eculizumab?
eculizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.